Zionexa USA and PETNET Solutions announce FDA approval of Cerianna™ (fluoroestradiol F18) JUST ANNOUNCED VIEW PRESS RELEASE Improving Patient Pathways and Quality of Life MOLECULAR IMAGING SOLUTIONS FOCUSED ON Launch In-vivo Biomarkers for Molecular Imaging NEXT GENERATION VIEW PIPELINE
Who we are
A leader in molecular imaging in-vivo biomarkers for targeted therapies in oncology
Zionexa combines proven heritage with a pioneering approach to deliver innovation, excellence and unparalleled service. Find out more about us.
IN-VIVO BIOMARKERS
We are dedicated to developing in-vivo biomarkers to guide targeted therapies for precision medicine. In-vivo biomarkers ensure a personal diagnosis for every patient, a selection of an effective treatment, as well as a therapy monitoring.
MOLECULAR IMAGING
Molecular imaging is a non-invasive technique which allows healthcare professionals to visualize molecules and their function within the cell. Molecular imaging is used for initial diagnosis and monitoring of cancer tumors.
ONCOLOGY
In 2018, 18.1 million new cancer cases have been reported in the world. Everyday, we work to develop biomarkers specialized in oncology to improve the patient’s pathway and quality of life.
EXPERTISE
Our team is composed of international experts who have more than 20 years of experience in radiopharmaceutical industry and molecular imaging.
